Medication treatment complexity and adherence in children with CKD.

BACKGROUND AND OBJECTIVES The complexity of CKD management in children is increased by the number of comorbid conditions. This study assessed the prevalence of comorbidities in pediatric CKD and the frequency with which multiple comorbidities present together by assessing prevalent medication use by CKD stage and diagnosis and their association with clinical or sociodemographic factors. The association between number and frequency of dosing of medications prescribed and self-report of nonadherence was also assessed. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS In this cross-sectional analysis of the Chronic Kidney Disease in Children study, medication use at study entry grouped by indication was examined by CKD stage, diagnosis, age, race, ethnicity, income, and CKD duration. Multivariate adjusted predictors of medication use and clustering were examined. Nonadherence was assessed by self-report of missed medications in the past 7 days. RESULTS The 558 eligible participants had a median age of 11 years and median GFR of 44 ml/min per 1.73 m(2); 62% of participants were male and 78% had nonglomerular kidney disease. The number of medications for treatment of CKD comorbidities increased with advanced CKD stage (2.5-fold for stages IV versus II; P<0.001) and glomerular disease (1.4-fold versus nonglomerular; P<0.001). Three distinct medication clusters were identified that corresponded to treatment of glomerular disease, advanced renal tubular dysfunction, and proteinuric complications, respectively. Nonadherence was associated with increased medication dosing frequency (administration >2 times/d; P<0.001) but not the number of medications. CONCLUSIONS Medical therapy for children with CKD is complex and is affected by glomerular diagnosis, CKD stage, and medication frequency. The need for CKD-related medication treatment cannot be easily predicted by CKD staging alone. Poorer adherence was associated with increased medication frequency, but not with the number of medical problems needing treatment. Consolidating medical treatment and reducing medication frequency may improve adherence rates in children with CKD.

[1]  M. Witt,et al.  Randomization to Once-Daily Stavudine Extended Release/Lamivudine/Efavirenz Versus a More Frequent Regimen Improves Adherence While Maintaining Viral Suppression , 2008, HIV clinical trials.

[2]  F. Shaya,et al.  Effect of medication burden on persistent use of lipid-lowering drugs among patients with hypertension. , 2008, The American journal of managed care.

[3]  M. Gebregziabher,et al.  Using quantile regression to investigate racial disparities in medication non-adherence , 2011, BMC medical research methodology.

[4]  A. Eddy Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. , 1994, Journal of the American Society of Nephrology : JASN.

[5]  K. Gauvreau,et al.  Impact of medication non-adherence on survival after pediatric heart transplantation in the U.S.A. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  L. Brion,et al.  The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. , 1987, Pediatric clinics of North America.

[7]  Vivienne J. Zhu,et al.  Race and medication adherence and glycemic control: findings from an operational health information exchange. , 2011, AMIA ... Annual Symposium proceedings. AMIA Symposium.

[8]  S. Cole,et al.  Glomerular filtration rate via plasma iohexol disappearance: pilot study for chronic kidney disease in children. , 2006, Kidney international.

[9]  K. Buchacz,et al.  Factors associated with non-adherence to antiretroviral therapy in the SUN study , 2011, AIDS care.

[10]  Susan L. Furth,et al.  Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C , 2012, Kidney international.

[11]  M. Markell,et al.  Preferential adherence to immunosuppressive over nonimmunosuppressive medications in kidney transplant recipients. , 2010, Transplantation proceedings.

[12]  D. Batlle,et al.  Distal renal tubular acidosis: pathogenesis and classification. , 1982, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  S. Arora,et al.  Metabolic acidosis and progression of chronic kidney disease: incidence, pathogenesis, and therapeutic options. , 2012, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[14]  L. Dedík,et al.  Long-term follow-up of renal function in patients after surgery for obstructive uropathy , 2008, Pediatric Nephrology.

[15]  W. Frishman Importance of Medication Adherence in Cardiovascular Disease and the Value of Once-Daily Treatment Regimens , 2007, Cardiology in review.

[16]  Yi-Wen Chiu,et al.  Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[17]  Pamala A. Pawloski,et al.  Patient Characteristics Associated with Medication Adherence , 2013, Clinical Medicine & Research.

[18]  D. Batlle,et al.  Hyperkalemic distal renal tubular acidosis associated with obstructive uropathy. , 1981, The New England journal of medicine.

[19]  M. Kallen,et al.  Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naïve HIV patients , 2012, International journal of STD & AIDS.

[20]  Craig S. Wong,et al.  Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[21]  Stefan Esser,et al.  Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial. , 2013, The Journal of infectious diseases.

[22]  C. Alpers,et al.  The pathogenesis of tubulointerstitial disease associated with glomerulonephritis: the glomerular cytokine theory. , 1995, Mineral and electrolyte metabolism.

[23]  A. Eddy Progression in chronic kidney disease. , 2005, Advances in chronic kidney disease.

[24]  A. Lazzarin,et al.  Number of daily pills, dosing schedule, self‐reported adherence and health status in 2010: a large cross‐sectional study of HIV‐infected patients on antiretroviral therapy , 2013, HIV Medicine.

[25]  K. Hardinger,et al.  Influence of Pill Burden and Drug Cost on Renal Function After Transplantation , 2012, Pharmacotherapy.